Royal Adelaide Hospital

Running trials

• Not yet recruiting

  Swabs in Screening for HPV (SWISH)

  NCT07790601· Kirby Institute· Source

• Recruiting

  Primary Radiotherapy In MEtastatic Lung Cancer

  NCT07135882· Phase 3· Trans Tasman Radiation Oncology Group· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Safety and Efficacy of NRT6008 Administered in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Carcinoma (LAPC)

  NCT07555587· Phase 1· NRT MedTech Australia Pty Ltd· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction

  NCT07362446· Phase 2· Nyrada Pty Ltd· Source

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

  NCT07668388· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Takeda· Source

• Recruiting

  A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

  NCT07519772· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

  NCT07469891· Phase 1· Prelude Therapeutics Incorporated· Source

• Recruiting

  A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT07455851· Phase 1/2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

  NCT06980480· Phase 3· Takeda· Source

• Recruiting

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

  NCT07100730· Phase 3· Telix Pharmaceuticals (Innovations) Pty Limited· Source

• Recruiting

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Surgical Outcomes Research Centre (SOuRCe)· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  NCT07008118· Phase 1· Incyte Corporation· Source

• Recruiting

  A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

  NCT06628947· Phase 2· Kiora Pharmaceuticals, Inc.· Source

• Recruiting

  Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  NCT06824168· Phase 2· Daiichi Sankyo· Source

• Recruiting

  A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

  NCT06892522· Phase 1/2· AbbVie· Source

• Recruiting

  A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979375· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  NCT06902558· Phase 2· Calico Life Sciences LLC· Source

• Active, not recruiting

  A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

  NCT06917404· Phase 3· Paradigm Biopharmaceuticals Ltd.· Source

• Recruiting

  Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

  NCT07202078· Phase 2/3· Monash University· Source

• Recruiting

  Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

  NCT07202052· Phase 2/3· Monash University· Source

• Recruiting

  Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

  NCT07202091· Phase 2/3· Monash University· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

• Recruiting

  Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema

  NCT06825702· Phase 2· Kiora Pharmaceuticals, Inc.· Source

• Recruiting

  Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

  NCT07202065· Phase 2/3· Monash University· Source

• Recruiting

  Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

  NCT06510699· Phase 2· The University of Queensland· Source

• Active, not recruiting

  ASCEND CSP IDE Study

  NCT06830746· Abbott Medical Devices· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

  NCT06770933· Phase 2· Vantage Biosciences Ltd· Source

• Recruiting

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  NCT06717347· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

  NCT06456463· Phase 2· Stemline Therapeutics, Inc.· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· BioNTech SE· Source

• Recruiting

  International Care Bundle Evaluation in Cerebral Hemorrhage Research

  NCT06429332· Phase 4· Region Skane· Source

• Not yet recruiting

  Surgery and Reducing Ionizing Radiation of the Unknown Primary

  NCT06578871· Phase 2· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Recruiting

  RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

  NCT06798896· Phase 2· Supernus Pharmaceuticals, Inc.· Source

• Recruiting

  A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.

  NCT06701721· Phase 1· Therini Bio Pty Ltd· Source

• Recruiting

  A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT06669247· Phase 1/2· Regeneron Pharmaceuticals· Source

• Recruiting

  Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

  NCT06465953· Phase 3· Institut de Recherches Internationales Servier· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

  NCT06492837· Phase 2· Fondazione Italiana Linfomi - ETS· Source

• Recruiting

  Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

  NCT07612280· Phase 1/2· Jubilant Therapeutics Inc.· Source

• Recruiting

  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  NCT06561048· Phase 3· Corvus Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

  NCT06379789· Phase 1/2· Regeneron Pharmaceuticals· Source

Showing 50 of 187.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma10 recruiting
• Stroke9 recruiting
• Myeloproliferative neoplasms6 recruiting
• Childhood cancers5 recruiting
• Heart failure5 recruiting
• Myelodysplastic syndromes5 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Aortic stenosis3 recruiting
• Crohn's disease3 recruiting
• Haemophilia3 recruiting
• Hodgkin lymphoma3 recruiting
• Lung cancer3 recruiting
• Amyloidosis2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Coronary artery disease2 recruiting
• Follicular lymphoma2 recruiting
• Mantle cell lymphoma2 recruiting
• Melanoma2 recruiting
• Prostate cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• COPD1 recruiting
• Diabetic eye disease1 recruiting
• Epilepsy1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Hepatitis C1 recruiting
• HIV1 recruiting
• Lupus (SLE)1 recruiting
• Obesity1 recruiting
• Osteoporosis1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Polycystic kidney disease1 recruiting
• Retinitis pigmentosa1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thalassaemia1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Transscleral Selective Laser Trabeculoplasty Project

  NCT06833060· Lumibird Medical (Quantel Medical, Ellex Medical, Optotek)· Source

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Completed

  FOCALFLEX (CE Mark) Study

  NCT06271967· Abbott Medical Devices· Source

• Terminated

  To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

  NCT06488911· Phase 3· Intercept Pharmaceuticals· Source

• Completed

  VOLT-AF IDE Clinical Study

  NCT06223789· Abbott Medical Devices· Source

• Withdrawn

  The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

  NCT06291415· Phase 1· Hutchmed· Source

• Completed

  A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

  NCT06016088· Phase 1/2· Respirion Pharmaceuticals Pty Ltd· Source

• Withdrawn

  A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

  NCT05927012· Phase 2· Keros Therapeutics, Inc.· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

  NCT05583552· Phase 2· GCP-Service International West GmbH· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Assess the Safety of TPM502 in Adults With Celiac Disease

  NCT05660109· Phase 2· Topas Therapeutics GmbH· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· The George Institute· Source

• Terminated

  A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

  NCT05574010· Phase 1/2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source

• Completed

  A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

  NCT05282953· Phase 1/2· Kiora Pharmaceuticals, Inc.· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

  NCT05444972· AbbVie· Source

• Completed

  A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

  NCT05243342· Phase 1· Genentech, Inc.· Source

• Terminated

  Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

  NCT05305040· Phase 2/3· AlloVir· Source

• Completed

  A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis

  NCT04875754· Phase 1/2· ICM Biotech Australia Pty Ltd.· Source

• Completed

  Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)

  NCT05203224· Phase 2· University of Melbourne· Source

• Completed

  Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

  NCT05130970· Phase 2· CSL Behring· Source

• Completed

  An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

  NCT05223920· Phase 2· Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)· Source

• Completed

  Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

  NCT05199337· Phase 1/2· K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source

• Completed

  Does Eliminating Coffee Avoid Fibrillation?

  NCT05121519· University of California, San Francisco· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Novo Nordisk A/S· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

  NCT04903626· Phase 3· AbbVie· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Completed

  A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)

  NCT04659031· Phase 1· Abcuro, Inc.· Source

• Completed

  Comprehensive Geriatric Assessment for Frail Older People With Chronic Kidney Disease - The GOAL Trial

  NCT04538157· The University of Queensland· Source

• Completed

  A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

  NCT04438304· Phase 2· Clarity Pharmaceuticals Ltd· Source

• Completed

  Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

  NCT04750226· Phase 3· AbbVie· Source

• Terminated

  Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs

  NCT03981211· Kirby Institute· Source

• Completed

  Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

  NCT03969953· Phase 3· The George Institute· Source

• Completed

  Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

  NCT04323098· Phase 3· BioMarin Pharmaceutical· Source

• Completed

  Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy

  NCT04576689· Phase 2· Ripple Therapeutics Pty Ltd· Source

• Completed

  Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

  NCT04295538· Phase 2· AbbVie· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion

  NCT04454788· Phase 3· University of Melbourne· Source

• Terminated

  Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

  NCT04316013· Phase 3· Peter MacCallum Cancer Centre, Australia· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Phase 2/3· Galectin Therapeutics Inc.· Source

• Completed

  Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

  NCT04379050· Phase 3· AbbVie· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source

• Completed

  Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

  NCT04282018· Phase 1/2· BeiGene· Source

• Completed

  A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

  NCT04102020· Phase 3· AbbVie· Source

Showing 50 of 84.

Conditions

Diseases this institution publishes on or runs trials for.

• Atrial fibrillation67 works · 11 trials
• Systemic sclerosis (scleroderma)26 works · 4 trials
• Myeloproliferative neoplasms16 works · 14 trials
• Pompe disease9 works · 1 trial
• Myelodysplastic syndromes8 works · 10 trials
• Postural tachycardia syndrome (POTS)7 works · 0 trials
• Chronic myeloid leukaemia5 works · 3 trials
• Gastroparesis5 works · 0 trials